1 min listen
Are Virtual SIVs the Future?: Interview with Jennifer Brandl
Are Virtual SIVs the Future?: Interview with Jennifer Brandl
ratings:
Length:
24 minutes
Released:
Oct 28, 2021
Format:
Podcast episode
Description
Jennifer Brandl is the Associate Director of Clinical Operations at Kezar Life Sciences. She has 15 years of experience as a researcher and clinical operations specialist, and she is currently pursuing a Master’s degree in Data Science from the University of Wisconsin.Jennifer credits her prior experience at a smaller biotech company with giving her a critical foundation in clinical conduct and study execution. At Kezar, she leverages this expertise and her passion for research to support the company’s development of pioneering therapies and to change the lives of patients.Episode HighlightsThe elements of Jennifer’s expertise that have especially helped her drive success in the trials she managesThe benefits of functional service provider outsourcing modelsHow Kezar’s patient-centric nature had the company well prepared to navigate the COVID-19 pandemicThe greatest challenges Jennifer and Kezar experienced due to the pandemic, and some positive outcomesImportant considerations for organizations exploring home health optionsHow communication and relationship-building form the foundation of clinical trial workThe challenges and benefits she’s experienced conducting site initiation visits virtuallyHow best to prepare before updating or transforming site initiation processesWhat she believes is next for decentralized clinical trialsHow automation and tech adoption can help extract more insight from dataResources:Kezar Life SciencesJennifer Brandl on LinkedInConversations in Clinical Trial Readiness Interview Series
Released:
Oct 28, 2021
Format:
Podcast episode
Titles in the series (12)
Welcome to Conversations in Clinical Trial Readiness: Conversations in Clinical Trial Readiness, a series featuring life science executives who share their stories and insights related to clinical operations and clinical trial readiness. by Conversations in Clinical Trial Readiness